• Explore /
  • Poster
  • / A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Fatima H. Karzai

Medical Oncology Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD

Fatima H. Karzai , Avani Atul Shah , Michelle A. Ojemuyiwa , Ravi Amrit Madan , Andrea Borghese Apolo , Nancy Ann Dawson , Philip M. Arlen , Marc Robert Theoret , John Joseph Wright , Clara Chen , Jane B. Trepel , Anna Couvillon , Guinevere Chun , Nancy Harold , Seth M. Steinberg , Douglas K. Price , James L. Gulley , William Douglas Figg , William L. Dahut

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT01683994

Citation

J Clin Oncol 32, 2014 (suppl 4; abstr 108)

DOI

10.1200/jco.2014.32.4_suppl.108

Abstract #

108

Poster Bd #

G7

Abstract Disclosures

Similar Posters

First Author: Munjid Al Harthy

First Author: Jamal Alamiri

First Author: Megan Crumbaker

Poster

2014 Genitourinary Cancers Symposium

Biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.

Biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.

First Author: Bobby Chi-Hung Liaw